Tehrani Ali 4
4 · Zymeworks Inc. · Filed Jul 16, 2021
Insider Transaction Report
Form 4
Zymeworks Inc.ZYME
Tehrani Ali
DirectorChief Executive Officer
Transactions
- Sale
Common Shares
2021-07-16$36.00/sh−41,191$1,482,876→ 260,325 total - Sale
Common Shares
2021-07-15$36.00/sh−3,800$136,800→ 260,325 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-07-16−41,191→ 0 totalExercise: $4.26From: 2013-01-01Exp: 2022-01-01→ Common Shares (41,191 underlying) - Exercise/Conversion
Common Shares
2021-07-15$4.27/sh+3,800$16,231→ 264,125 total - Exercise/Conversion
Common Shares
2021-07-16$4.26/sh+41,191$175,651→ 301,516 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-07-15−3,800→ 41,191 totalExercise: $4.27From: 2013-01-01Exp: 2022-01-01→ Common Shares (3,800 underlying)
Holdings
- 55,511(indirect: By Spouse)
Common Shares
Footnotes (5)
- [F1]Pursuant to a 10b5-1 plan entered into May 13, 2021.
- [F2]The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.2713 using the Bank of Canada exchange rate for July 15, 2021 (CAD1.00 = $0.7954).
- [F3]All shares were sold at $36.00 per share.
- [F4]The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.2643 using the Bank of Canada exchange rate for July 16, 2021 (CAD1.00 = $0.7941).
- [F5]Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date of January 1, 2012 and (ii) remainder of underlying shares in 36 equal monthly installments on the last day of month following first anniversary of grant date.